相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
Santosh K. Gupta et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2012)
Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide
Ebrahim S. Delpassand et al.
THERANOSTICS (2012)
Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
Dik J. Kwekkeboom et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy
Samer Ezziddin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Anna Imhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Samer Ezziddin et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study
J. B. Cwikla et al.
ANNALS OF ONCOLOGY (2010)
Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Dik J. Kwekkeboom et al.
SEMINARS IN NUCLEAR MEDICINE (2010)
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats
Edgar J. Rolleman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
From outside to inside?: Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo 99mTc-DMSA-SPECT and molecular imaging
Flavio Forrer et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors
Andrea Frilling et al.
SURGERY (2006)
MDRD equations for estimation of GFR in renal transplant recipients
U Pöge et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
DJ Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity
WAP Breeman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies
TM Behr et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
End-stage renal disease after treatment with 90Y-DOTATOC
M Cybulla et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
[177Lu-DOTA0,Tyr3]octreotate:: comparison with [111In-DTPA0]octreotide in patients
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:: A clinical phase II study
C Waldherr et al.
ANNALS OF ONCOLOGY (2001)
Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma
MP Stoffel et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2001)
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
G Paganelli et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy
S Moll et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2001)
分享论文
